Cheng Zou

Changsha, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Increasing Cancer Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival.

Increasing Cancer Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival.

Journal: bioRxiv : the preprint server for biology

Published: June 03, 2025

Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy.

Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy.

Journal: Cancer letters

Published: May 07, 2024

Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation.

Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation.

Journal: Science advances

Published: April 03, 2024

Stabilization of RRBP1 mRNA via an m6A-dependent manner in prostate cancer constitutes a therapeutic vulnerability amenable to small-peptide inhibition of METTL3.

Stabilization of RRBP1 mRNA via an m6A-dependent manner in prostate cancer constitutes a therapeutic vulnerability amenable to small-peptide inhibition of METTL3.

Journal: Cellular and molecular life sciences : CMLS

Published: March 27, 2024

An integrated ceRNA network identifies miR-375 as an upregulated miRNA playing a tumor suppressive role in aggressive prostate cancer.

An integrated ceRNA network identifies miR-375 as an upregulated miRNA playing a tumor suppressive role in aggressive prostate cancer.

Journal: Oncogene

Published: July 17, 2023

Comprehensive Characterization of the Integrin Family Across 32 Cancer Types.

Comprehensive Characterization of the Integrin Family Across 32 Cancer Types.

Journal: Genomics, proteomics & bioinformatics

Published: July 08, 2023

A m6Avalue predictive of prostate cancer stemness, tumor immune landscape and immunotherapy response.

A m6Avalue predictive of prostate cancer stemness, tumor immune landscape and immunotherapy response.

Journal: NAR cancer

Published: December 10, 2021

Integrins regulate stemness in solid tumor: an emerging therapeutic target.

Integrins regulate stemness in solid tumor: an emerging therapeutic target.

Journal: Journal of hematology & oncology

Published: July 19, 2021

Bone marrow-confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia.

Bone marrow-confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia.

Journal: The Journal of clinical investigation

Published: June 24, 2021

The spliceosome as a new therapeutic vulnerability in aggressive prostate cancer.

The spliceosome as a new therapeutic vulnerability in aggressive prostate cancer.

Journal: Molecular & cellular oncology

Published: September 18, 2020

RBM38 in cancer: role and mechanism.

RBM38 in cancer: role and mechanism.

Journal: Cellular and molecular life sciences : CMLS

Published: April 09, 2020

Showing 1-11 of 11

Last Updated: 09/26/2026